Goldman Sachs
ATYR

Goldman Sachs’s aTyr Pharma ATYR Stock Holding History

Goldman Sachs’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Buy
641,208
+357,972
+126% +$234K ﹤0.01% 5865
2026
Q1 		$221K Sell
283,236
-62,351
-18% -$52.6K ﹤0.01% 6038
2025
Q4 		$271K Sell
345,587
-342,578
-50% -$281K ﹤0.01% 5915
2025
Q3 		$496K Buy
688,165
+651,890
+1,797% +$2.95M ﹤0.01% 5518
2025
Q2 		$184K Sell
36,275
-346,042
-91% -$1.36M ﹤0.01% 5687
2025
Q1 		$1.15M Buy
382,317
+120,496
+46% +$439K ﹤0.01% 4572
2024
Q4 		$948K Buy
+261,821
New +$793K ﹤0.01% 4859
2024
Q2 		– Sell
-217,233
Closed -$424K – 5980
2024
Q1 		$424K Buy
217,233
+73,663
+51% +$128K ﹤0.01% 4824
2023
Q4 		$202K Buy
+143,570
New +$184K ﹤0.01% 5149
2022
Q1 		– Sell
-18,512
Closed -$138K – 6960
2021
Q4 		$138K Buy
+18,512
New +$154K ﹤0.01% 6031
2017
Q3 		– Sell
-1,582
Closed -$75K – 6896
2017
Q2 		$75K Sell
1,582
-709
-31% -$33.2K ﹤0.01% 6235
2017
Q1 		$112K Sell
2,291
-3,313
-59% -$151K ﹤0.01% 6013
2016
Q4 		$169K Sell
5,604
-1,048
-16% -$43K ﹤0.01% 5880
2016
Q3 		$296K Buy
6,652
+4,305
+183% +$186K ﹤0.01% 5492
2016
Q2 		$91K Sell
2,347
-707
-23% -$32.9K ﹤0.01% 6175
2016
Q1 		$168K Buy
3,054
+2,100
+220% +$160K ﹤0.01% 5756
2015
Q4 		$131K Sell
954
-3,292
-78% -$468K ﹤0.01% 6021
2015
Q3 		$610K Sell
4,246
-1,291
-23% -$294K ﹤0.01% 4946
2015
Q2 		$1.44M Buy
+5,537
New +$1.72M ﹤0.01% 4182

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's ATYR Position: Q2 2026 in Review

Goldman Sachs increased its aTyr Pharma (ATYR) stake by 126% in Q2 2026, buying an estimated $234K and bringing the position to 641,208 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #5865.

Goldman Sachs first reported a position in ATYR in Q2 2015 and has held it in 19 quarters since. The position peaked at $1.44M in Q2 2015. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Goldman Sachs held 641,208 shares of aTyr Pharma worth $383K as of Q2 2026.
  • Goldman Sachs bought 357,972 aTyr Pharma shares in Q2 2026, an estimated $234K.
  • aTyr Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5865 holding.
  • Goldman Sachs first reported a position in aTyr Pharma in Q2 2015 and has held it in 19 quarters since.
  • Goldman Sachs's aTyr Pharma position peaked at $1.44M in Q2 2015.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.